Uso clínico da testosterona e seus derivados químicos: uma revisão narrativa
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Revisar as principais publicações científicas nos últimos 10 anos (2012-2022) sobre as indicações terapêuticas da testosterona e de seus derivados químicos. Revisão bibliográfica: Não é de hoje que a Testosterona e seus derivados químicos, os Esteróides Anabólicos Androgênicos, fazem parte do arsenal terapêutico da medicina moderna. Todavia, sua utilização indiscriminada, abusiva e sem acompanhamento médico devido, acarreta diversos efeitos colaterais indesejados e complicações, gerando uma grande polêmica em torno de sua aplicabilidade. No entanto, observa-se dados na literatura que sustentam seus resultados benéficos no tratamento de diversas entidades patológicas que cursam com hipogonadismo, sarcopenia, e perda funcional, por exemplo. Nesse sentido, o conhecimento das corretas indicações clínicas e posologias adequadas desses hormônios androgênicos garante mais oportunidades terapêuticas a determinadas condições deletérias ao indivíduo. Considerações finais: Apesar das evidências positivas demonstradas nesta revisão, esta é uma área da medicina que ainda carece de mais atenção e pesquisas, sobretudo no âmbito do controle dos indesejados efeitos colaterais, das consequências do uso recreativo e indiscriminado destes hormônios, e também da desmistificação da sua prescrição terapêutica por parte dos profissionais médicos contemporâneos.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. ANDERSON JL, et al. Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. Am J Cardiol, 2016; 117(5): 794–9.
3. BEBO JUNIOR BF, et al. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J Immunol, 1999; 162: 35–40.
4. BEVILACQUA G, et al. Percepções sobre risco e efeitos do uso e consumo de esteroides anabolizantes por praticantes de musculação. Caderno Educação física e Esporte: Paraná, 2016; 14(2): 07.
5. BEZERRA A, et al. Riscos relacionados ao uso de anabolizantes esteróides para fins estéticos. Research, Society and Development, 2022; 11(7): e18811729983.
6. BOJESEN A, et al. Klinefelter syndrome, type 2 diabetes and metabolic syndrome: the impact of body composition. Mol Hum Reprod, 2010; 16: 396–401.
7. BREX PA, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. New England Journal of Medicine, 2002; 158-164.
8. CHAPMAN IM, et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr, 2009; 89: 880-9.
9. CHEETHAM TC, et al. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency. JAMA Intern Med, 2017; 177(4): 491–9.
10. CHITNIS T. The role of testosterone in MS risk and course. Multiple Sclerosis Journal, 2018; 24(1): 36-4.
11. DIAZ EC, et al. Effects of pharmacological interventions on muscle protein synthesis and breakdown in recovery from burns. Burns, 2015; 41(4): 649-657.
12. FINKLE WD, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 2014; 9(1): e85805.
13. FREEMAN ER, et al. A brief history of testosterone. The Journal Of Urology, 2001; 165: 371- 373. 14.
14. GARCÍA-CRUZ E, ALCARAZ A. Testosterone deficiency syndrome: Diagnosis and treatment. Actas Urol Esp (Engl Ed), 2020; 44(5): 294-300.
15. GLENN R, et al. Association of Sex Hormones With Sexual Function, Vitality, and Physical Function of Symptomatic Older Men With Low Testosterone Levels at Baseline in the Testosterone Trials. The Journal of Clinical Endocrinology & Metabolism, 2015; Pages 1146–1155G.
16. GUS EI, et al. Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned. Burns, 2020, 46(1): 19-32.
17. HERNDON D, et al. Reversal of Growth Arrest with the Combined Administration of Oxandrolone and Propranolol in Severely Burned Children. Annals of surgery, 2016; 264(3): 421–428.
18. HOST C, et al. The role of hypogonadism in Klinefelter Syndrome. Asian J Androl., 2014; 16: 185-91. MORLEY JE. Sarcopenia in the Elder, Family Practice, 2012; 29(suppl_1): i44–i48.
19. HOBERMAN JM. Testosterone Dreams: Rejuvenation, aphrodisia, doping. University of California Press, 2005.
20. KLAUDE M, et al. Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis. Clin Sci (Lond), 2012; 122(3): 133–42.
21. KRUMHOLZ HM. Post-hospital syndrome–an acquired, transient condition of generalized risk. N Engl J Med., 2013; 368: 100–102.
22. MORGUNOV LY, et al. Hypogonadism and its treatment after ischemic stroke in men with type 2 diabetes mellitus. The Aging Male, 2020, 23(1): 71-80.
23. MAVROS Y, et al. Oxandrolone enhances resistance training in older women. Medicine and Science in Sport and Exercise, 2015; 47(1): 2257-2267.
24. DAVIS MP, PANIKKAR P. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Annals of Palliative Medicine, 2019; 8(1).
25. MORLEY JE. Weight loss in older persons: new therapeutic approaches. Curr Pharm Des, 2007, 13: 3637-47.
26. NIGHTINGALE TE, et al. Body composition changes with testosterone replacement therapy following spinal cord injury and aging: A mini review. J Spinal Cord Med, 2018; 41(6): 624-636.
27. DEER RR, et al. A Randomized Controlled Pilot Trial of Interventions to Improve Functional Recovery After Hospitalization in Older Adults: Feasibility and Adherence. The Journals of Gerontology: Series A, 2018; 2: 187–193.
28. ROJAS Y, et al. Burns: an update on current pharmacotherapy. Expert Opin Pharmacother, 2012, 13(17): 2485-94.
29. SAAD F, et al. Testosterone Deficiency and Testosterone Treatment in Older Men. Gerontology, 2017, 63: 144-156.
30. SRINIVAS-SHANKAR U, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab, 2010; 95(2): 639–50.
31. TAUCHEN J, et al. Medicinal Use of Testosterone and Related Steroids Revisited. Molecules, 2021; 26(4): 1032.
32. THOMAS W, et al. Effects of Testosterone Supplementation for 3 Years on Muscle Performance and Physical Function in Older Men. The Journal of Clinical Endocrinology & Metabolism, 2017; 583–593.
33. VIGEVENO RM, et al. Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration. Journal of Magnetic Resonance Imaging: JMRI, 2012; 1-19.
34. WOSNITZER MS, PADUCH DA. Endocrinological issues and hormonal manipulation in children and men with Klinefelter syndrome. Am J Med Genet Part C Semin Med Genet, 2013; 163C: 16–26.
35. WRIGHT TJ, et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women. J Cachexia Sarcopenia Muscle, 2018; 9(3): 482-496.
36. YABLUCHANSKIY A, et al. Is Testosterone Replacement Therapy in Older Men Effective and Safe? Drugs Aging, 2019; 36(11): 981-989.